Health-related quality of life among patients with metastatic prostate cancer. (Q52003821)

19 April 2018

title

Health-related quality of life among patients with metastatic prostate cancer. (English)

1 reference

19 April 2018

1 reference

1 reference

Albertsen PC

1

1 reference

19 April 2018

Aaronson NK

2

1 reference

19 April 2018

Muller MJ

3

1 reference

19 April 2018

Keller SD

4

1 reference

19 April 2018

Ware JE Jr

5

1 reference

19 April 2018

language of work or name

English

0 references

publication date

1 February 1997

1 reference

19 April 2018

published in

Urology

1 reference

19 April 2018

volume

49

1 reference

19 April 2018

issue

2

1 reference

19 April 2018

page(s)

207-16; discussion 216-7

1 reference

19 April 2018

Measuring health related quality of life in men with prostate cancer.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900485-2

7 January 2021

Quality of life after radical retropubic prostatectomy for carcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900485-2

7 January 2021

Quality of life 12 months after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900485-2

7 January 2021

RTOG's first quality of life study—RTOG 90-20: A phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900485-2

7 January 2021

A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900485-2

7 January 2021

Survival and quality of life of patients with stage D1 (T1-3 pN1-2 M0) prostate cancer. Radical prostatectomy plus androgen deprivation versus androgen deprivation alone.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900485-2

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900485-2

7 January 2021

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900485-2

7 January 2021

The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900485-2

7 January 2021

The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900485-2

7 January 2021

Quality of life in patients with prostatic cancer. A feasibility study. The Members of Quality of Life Committee of the EORTC Genitourinary Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900485-2

7 January 2021

Quality of life and treatment of hormone resistant metastatic prostatic cancer. The EORTC Genito-Urinary Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900485-2

7 January 2021

The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900485-2

7 January 2021

Quality of life in adult survivors of lung, colon and prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900485-2

7 January 2021

Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900485-2

7 January 2021

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900485-2

7 January 2021

10.1016/S0090-4295(96)00485-2

Identifiers

DOI

1 reference

19 April 2018

1 reference

19 April 2018